Richard B. Toupence
Merck & Co.
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Richard B. Toupence.
Tetrahedron | 2001
Thomas F. Walsh; Richard B. Toupence; Feroze Ujjainwalla; Jonathan R. Young; Mark T. Goulet
Abstract A practical synthesis of (S)-β-methyl-2-aryltryptamine based gonadotropin releasing hormone antagonists which features a palladium-catalyzed Larock indole synthesis and a palladium-catalyzed Suzuki–Miyaura sequence to install the 2-position aryl substituent is reported.
Bioorganic & Medicinal Chemistry Letters | 2000
Thomas F. Walsh; Richard B. Toupence; Jonathan R. Young; Song X. Huang; Feroze Ujjainwalla; Robert J. DeVita; Mark T. Goulet; Matthew J. Wyvratt; Michael H. Fisher; Jane-Ling Lo; Ning Ren; Joel B. Yudkovitz; Yi Tien Yang; Kang Cheng; Roy G. Smith
SAR studies which focused upon the C-6 position of a recently described series of quinolone gonadotropin releasing hormone antagonists are reported. Synthetic access to diverse quinolone-6-carboxamides was achieved via the palladium-catalyzed amino-carbonylation reactions of iodide 4 with various amines. Amides related to 9y were especially potent, functional antagonists of rat and human GnRH receptors.
Bioorganic & Medicinal Chemistry Letters | 2010
John S. Debenham; Christina B. Madsen-Duggan; Richard B. Toupence; Thomas F. Walsh; Junying Wang; Xinchun Tong; Sanjeev Kumar; Julie Lao; Tung M. Fong; Jing Chen Xiao; Cathy R.-R.C. Huang; Chun-Pyn Shen; Yue Feng; Donald J. Marsh; D. Sloan Stribling; Lauren P. Shearman; Alison M. Strack; Mark T. Goulet
The synthesis, SAR and binding affinities of cannabinoid-1 receptor (CB1R) inverse agonists based on furo[2,3-b]pyridine scaffolds are described. Food intake, mechanism specific efficacy, pharmacokinetic, and metabolic evaluation of several of these compounds indicate that they are effective orally active modulators of CB1R.
Drug Metabolism and Disposition | 2010
Thomas J. Bateman; John S. Debenham; Christina B. Madsen-Duggan; Richard B. Toupence; Thomas F. Walsh; Quang Truong; Scott A. Bradley; George A. Doss; Sanjeev Kumar; Vijay Bhasker G. Reddy
MRL-1, a cannabinoid receptor-1 inverse agonist, was a member of a lead candidate series for the treatment of obesity. In rats, MRL-1 is eliminated mainly via metabolism, followed by excretion of the metabolites into bile. The major metabolite M1, a glutathione conjugate of MRL-1, was isolated and characterized by liquid chromatography/mass spectrometry and NMR spectroscopic methods. The data suggest that the t-butylsulfonyl group at C-2 of furopyridine was displaced by the glutathionyl group. In vitro experiments using rat and monkey liver microsomes in the presence of reduced glutathione (GSH) showed that the formation of M1 was independent of NADPH and molecular oxygen, suggesting that this reaction was not mediated by an oxidative reaction and a glutathione S-transferase (GST) was likely involved in catalyzing this reaction. Furthermore, a rat hepatic GST was capable of catalyzing the conversion of MRL-1 to M1 in the presence of GSH. When a close analog of MRL-1, a p-chlorobenzenesulfonyl furopyridine derivative (MRL-2), was incubated with rat liver microsomes in the presence of GSH, p-chlorobenzene sulfinic acid (M2) was also identified as a product in addition to the expected M1. Based on these data, a mechanism is proposed involving direct nucleophilic addition of GSH to sulfonylfuropyridine, resulting in an unstable adduct that spontaneously decomposes to form M1 and M2.
Archive | 1997
Thomas W. Doebber; Joel P. Berger; Gregory D. Berger; Mark D. Leibowitz; David E. Moller; John T. Olson; Arthur A. Patchett; Richard B. Toupence
Archive | 1994
Scott W. Bagley; Theodore P. Broten; Prasun K. Chakravarty; Daljit S. Dhanoa; Kenneth J. Fitch; William J. Greenlee; Nancy J. Kevin; Gerard R. Kieczykowski; Douglas J. Pettibone; James R. Tata; Ralph A. Rivero; Thomas F. Walsh; David L. Williams; Jay M. Matthews; Richard B. Toupence
Archive | 1997
Alan D. Adams; Joel P. Berger; Gregory D. Berger; Kenneth J. Fitch; Donald W. Graham; Anthony B. Jones; Langen Derek Von; Mark D. Leibowitz; David E. Moller; Arthur A. Patchett; Conrad Santini; Soumya P. Sahoo; Richard L. Tolman; Richard B. Toupence; Thomas F. Walsh
Archive | 2003
Richard B. Toupence; John S. Debenham; Mark T. Goulet; Christina B. Madsen-Duggan; Thomas F. Walsh; Shrenik K. Shah
Journal of Medicinal Chemistry | 2001
Robert J. DeVita; Thomas F. Walsh; Young; Jinlong Jiang; Feroze Ujjainwalla; Richard B. Toupence; Mamta Parikh; Song X. Huang; Fair Ja; Mark T. Goulet; Matthew J. Wyvratt; Jane-Ling Lo; Ning Ren; Joel B. Yudkovitz; Yi-Tien Yang; Kang Cheng; Jisong Cui; Mount G; Susan P. Rohrer; James M. Schaeffer; Linda Rhodes; Jennifer E. Drisko; Erin McGowan; D. E. Macintyre; Stella H. Vincent; Carlin; Cameron J; Roy G. Smith
Bioorganic & Medicinal Chemistry Letters | 2005
Laura C. Meurer; Paul E. Finke; Sander G. Mills; Thomas F. Walsh; Richard B. Toupence; Mark T. Goulet; Junying Wang; Xinchun Tong; Tung M. Fong; Julie Lao; Marie-Therese Schaeffer; Jing Chen; Chun-Pyn Shen; D. Sloan Stribling; Lauren P. Shearman; Alison M. Strack; Lex H.T. Van der Ploeg